Download PDF
Drug Res (Stuttg) 2023; 73(03): 164-169
DOI: 10.1055/a-1974-9028
Original Article

Molecular Docking Studies of Rifampicin – rpoB complex: Repurposing Drug Design Implications for against Plasmodium falciparum Malaria through a Computational Approach

Upasana Yadav
1   Amity School of Applied Sciences Lucknow, Amity University Uttar Pradesh, Lucknow, India
,
Jaya Pandey
1   Amity School of Applied Sciences Lucknow, Amity University Uttar Pradesh, Lucknow, India
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Malaria is one of the world’s most devastating diseases, infecting well over 300 million people annually and killing between 2 and 3 million worldwide. Increasing parasite resistance to many existing drugs is exacerbating disease. Resistance to commonly used malarial drugs is increasing the need to develop new drugs urgently. Due to the slow pace and substantial costs of new drug development, repurposing of old drugs which is recently increasingly becoming an attractive proposition of highly efficient and effective way of drug discovery led us to study the drug rifampicin for this purpose. The present paper aims to investigate the route of Plasmodium falciparum apicoplast-targeted proteins that putatively encode β subunits of RNA polymerase with an objective to develop an effective antimalarial drug. Homology searching for conserved binding site to the rifampicin drug and the functional analysis of rpoB gene were done. Multiple Sequence alignment analysis of rpoB was compared with that in E.coli – rpoB and M. tuberculosis – rpoB. Docking studies of Rifampicin – rpoB complex was also done for finding binding affinity. The results of computational studies showed that rifampicin is a potential drug for malaria.

Keywords

Antimalarial drugs - drug repurposing - rifampicin - parasite resistance - apicoplast - rpoB gene


Publication History

Received: 01 August 2022

Accepted: 15 October 2022

Article published online:
09 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hyde JE. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect 2002; 4: 165-174 DOI: 10.1016/s1286-4579(01)01524-6..
    CrossrefPubMedGoogle Scholar
  • 2 Lei ZN, Xun ZW, Dong S, Yang DH, Zhang L, Ke Z, Zou C, Chen ZS.. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19 pharmthera 2020; DOI: 10.1016/j.pharmthera.2020.107672.
    CrossrefPubMed
  • 3 Li Y, Loureiro A, Nguyen M, Laurent M, Bijani C, Benoit-Vical F, Robert A, Liu Y. Meunier B. Synthesis and Antimalarial Activities of New Hybrid Atokel. Molecules 2022; DOI: 10.1002/open.202200064.
    CrossrefPubMedGoogle Scholar
  • 4 Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, Ade MP, Lucchi NW, Grant Q, Udhayakumar V, Alexandre JS, Demar M, Ringwald P, Neafsey DE, Fidock DA, Musset L.. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. Elife 2020; DOI: 10.7554/eLife.51015..
    CrossrefPubMedGoogle Scholar
  • 5 Murithi JM, Pascal C, Bath J, Boulenc X, Gnädig NF, Pasaje CFA, Rubiano K, Yeo T, Mok S, Klieber S, Desert P, Jiménez-Díaz MB, Marfurt J, Rouillier M, Cherkaoui-Rbati MH, Gobeau N, Wittlin S, Uhlemann AC, Price RN, Wirjanata G, Noviyanti R, Tumwebaze P, Cooper RA, Rosenthal J, Sanz LM, Gamo FJ, Joseph J, Singh S, Bashyam S, Augereau JM, Giraud E, Bozec T, Vermat T, Tuffal G, Guillon JM, Menegotto J, Sallé L, Louit G, Cabanis MJ, Nicolas MF, Doubovetzky M, Merino R, Bessila N, Angulo-Barturen I, Baud D, Bebrevska L, Escudié F, Niles JC, Blasco B, Campbell S, Courtemanche G, Fraisse L, Pellet A, Fidock DA, Leroy D.. The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance. Sci Transl Med 2021; DOI: 10.1126/scitranslmed.abg6013.
    CrossrefPubMedGoogle Scholar
  • 6 Lozovsky ER, Chookajorn T, Brown KM, Imwong M, Shaw PJ, Kamchonwongpaisan S, Neafsey DE, Weinreich DM, Hartl DL.. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci 2009; 12025-12030 DOI: 10.1073/pnas.0905922106.
    CrossrefPubMedGoogle Scholar
  • 7 Miguel-Blanco C, Murithi JM, Benavente ED.. The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957. Sci Rep 11 2021; DOI: 10.1038/s41598-021-81343-z.
    CrossrefPubMedGoogle Scholar
  • 8 Musyoka TM, Njuguna JN, Bishop ÖT.. Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide based inhibitor design. Malar J 2019; 18: 159 DOI: 10.1186/s12936-019-2790-2.
    CrossrefPubMedGoogle Scholar
  • 9 Verschuere J, Decroo T, Lim D.. Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. Malar J 2017; 16: 81 DOI: 10.1186/s12936-017-1732-0.
    CrossrefPubMedGoogle Scholar
  • 10 Grobbelaar M, Louw GE, Sampson SL, Helden PDv, Donald PR, Warren RM.. Evolution of rifampicin treatment for tuberculosis. Epub 2019; DOI: 10.1016/j.meegid.2019.103937..
    CrossrefPubMedGoogle Scholar
  • 11 Stortz JF, Rosario MD, Singer M, Wilkes JM, Meissner M, Das S.. Formin-2 drives polymerisation of actin filaments enabling segregation of apicoplasts and cytokinesis in Plasmodium falciparum. eLife 2019; 8: e49030 DOI: 10.7554/eLife.49030.
    CrossrefPubMedGoogle Scholar
  • 12 Stortz JF, Singer MJ, Wilkes M, Meissner M, Das S.. Formin-2 drives intracellular polymerisation of actin filaments enabling correct segregation of apicoplasts in Plasmodium falciparum and Toxoplasma gondii. bioRxiv 2018; 488528 DOI: 10.1101/488528.
    CrossrefPubMedGoogle Scholar
  • 13 D’Alessandro S, Scaccabarozzi D, Signorini L, Perego F, Ilboudo DP, Ferrante P, Delbue S.. The Use of Antimalarial Drugs against Viral Infection. Microorganisms 2020; 8: 85 DOI: 10.3390/microorganisms8010085.
    CrossrefPubMedGoogle Scholar
  • 14 Belete TM.. Recent Progress in the Development of New Antimalarial Drugs with Novel Targets. Drug Des Devel Ther 2020; 14: 3875-3889 DOI: 10.2147/DDDT.S265602.
    CrossrefPubMedGoogle Scholar
  • 15 Sarhan AA, Ashour NA, Al-Karmalawy AA. The journey of antimalarial drugs against SARS-CoV-2: Review article. IMU 2021; 24: 100604 ISSN 2352-9148, https://doi.org/10.1016/j.imu.2021.100604
    PubMedGoogle Scholar
  • 16 Duarte D, Vale N.. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomolecules 2020; 10 ISSN 2218-273X DOI: 10.3390/biom10121623.
    CrossrefPubMedGoogle Scholar
  • 17 Carvalho DPL, Kreidenweiss A, Jana H.. Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action. MDPI 2021; 26 ISSN 1420-3049 DOI: 10.3390/molecules26082304. bb.
    CrossrefPubMedGoogle Scholar
  • 18 Stadelmann BL, Rufener R, Hemphill A.. Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis. INT PARACETOL-DRUG 2020; 13: 121-129 ISSN 2211-3207 DOI: 10.1016/j.ijpddr.2020.06.002.
    CrossrefPubMedGoogle Scholar
  • 19 Fontinha D, Moules I, Prudêncio M.. Repurposing Drugs to Fight Hepatic Malaria Parasites. Molecules 2020; 25: 3409 DOI: 10.3390/molecules25153409.
    CrossrefPubMedGoogle Scholar
  • 20 Cooper RA, Kirkman L.. Can repurposing drugs play a role in malaria control. J Exp Med 202 Epub 2021; Nov 22. PMID.1 218: e20211512 DOI: 10.1084/jem.20211512.
    CrossrefPubMedGoogle Scholar
  • 21 Pandey SM, Saraswat K, Kant R, Mohit S, Pandey J. Microwave Assisted Green Synthesis and Entomological Characteristic Studies of Novel Chromium(III) complexes of dithiocarbamates derived from glycine, alanine, proline, Valine and Norvaline α-amino acids. Journal of the Indian Chemical Society 2022; 100711 DOI: 10.1016/j.jics.2022.100711.
    CrossrefPubMedGoogle Scholar
  • 22 Satpute S, Polkam N, Kant R, Anireddy JS. Design, synthesis and evaluation of 4H-Chromene-4-one analogues as potential Anti-bacterial and Anti-fungal agents. Chem. Biol. Lett. 2020; 7: 27-40
    PubMedGoogle Scholar
  • 23 Iyer JM, Khare A, Pandey J. Insilico Docking Study of Isoxazole Indole Linked Resorcinol Derivatives as Promising Selective Estrogen Receptor Modulators & Anticancer Drugs. Drug Res 2022; 633-639
    PubMedGoogle Scholar
  • 24 Pandey J, Dubey R, Kate A, Prasad B, Sinha A, Mishra MS.. Nanomedicines: A Focus on Nanomaterials as Drug Delivery System with Current Trends and Future Advancement. Drug Research 2022; 2: 355-366 DOI: 10.1055/a-1824-4619.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Pandey A, Dubey R, Kant R, Pandey J. Synthesis and computational studies of potent antimicrobial and anticancer indolone scaffolds with spiro cyclopropyl moiety as a novel design element. Journal of the Indian Chemical Society 2022; 99: 100539 DOI: 10.1016/j.jics.2022.100539.
    CrossrefPubMedGoogle Scholar
  • 26 Mittal S, Chakole CM, Sharma A, Pandey J, Chauhan MK.. An Overview of Green Synthesis and Potential Pharmaceutical Applications of Nanoparticles as Targeted Drug Delivery System in Biomedicines. Drug Research 2022; 72: 274-283 DOI: 10.1055/a-1801-6793.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Pankaj SK, Hanuman PS, Chandrashekhar CM. Application of Vitamin E TPGS in ocular therapeutics – Attributes beyond excipient. Journal of the Indian Chemical Society 2022; 99: 100387-100391 DOI: 10.1016/j.jics.2022.100387.
    CrossrefPubMedGoogle Scholar
  • 28 Chandrashekhar CM, Sahoo PK, Pandey J, Chauhan MK. A green chemistry approach towards synthesizing hydrogel for sustained ocular delivery of brinzolamide: In vitro and ex vivo evaluation. Journal of the Indian Chemical Society 2022; 99: 323-329 DOI: 10.1016/j.jics.2021.100323.
    CrossrefPubMedGoogle Scholar
  • 29 Arora G, Shrivastava R, Kuma P, Krishnamurthy D, Matharu M. Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. Current Research in Green and Sustainable Chemistry 2021; 4: 100097-100103 DOI: 10.1016/j.crgsc.2021.100097.
    CrossrefPubMedGoogle Scholar
  • 30 Pasche V, Laleu B, Keiser J.. Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni. Parasites Vectors 2018; 11: 298
    CrossrefPubMedGoogle Scholar
  • 31 Mishra M, Sharma M, Dubey R. Green synthesis interventions of pharmaceutical industries for sustainable development. Current Research in Green and Sustainable Chemistry 4 2021; 100174 ISSN 2666-0865, https://doi.org/10.1016/j.crgsc.2021.100174
    CrossrefPubMedGoogle Scholar
  • 32 Swale, Christopher and Bellini, Valeria and Bowler, Matthew W. and Flore, Nardella and Pinchart.B, Pierre.M and Cannella, Dominique and Belmudes, Lucid and Mas, Caroline and Cout, Yohann and Laurent, Fabrice and Scherf, Artur and Bougdour, Alexandre and Hakimi, Ali.M A drug repurposing screen identifies altiratinib as a selective inhibitor of a key regulatory splicing kinase and a potential therapeutic for toxoplasmosis and malaria. bioRxiv 2021; DOI: 10.1101/2021.11.03.467097.
    CrossrefPubMedGoogle Scholar
  • 33 Augustin Y, Staines H.M, Krishna S. Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing, pharmthera 2020; DOI: 10.1016/.pharmthera. 2020.107706.
    CrossrefPubMed
  • 34 Farha M.A, Brown E.D. Drug repurposing for antimicrobial discovery. Nat Microbiol 4: 565-577 2019; DOI: 10.1038/s41564-019-0357-1.
    CrossrefPubMedGoogle Scholar